Third quarter 2017 financial results from Amgen (Nasdaq: AMGN) show a slight fall in revenue, coming in around analysts’ expectations at $5.8 billion.
The company said it was nonetheless raising its guidance, due to “strong, volume-driven growth in our recently launched products.”
Shares in the Californian biotech drifted half a percentage point in after-hours trading, to $176.50, as investors sought to interpret the news.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze